200 related articles for article (PubMed ID: 10626092)
1. Pharmacokinetic and pharmacodynamic responses to chronic administration of the selective serotonin reuptake inhibitor citalopram in rats.
Wikell C; Apelqvist G; Carlsson B; Hjorth S; Bergqvist PB; Kugelberg FC; Ahlner J; Bengtsson F
Clin Neuropharmacol; 1999; 22(6):327-36. PubMed ID: 10626092
[TBL] [Abstract][Full Text] [Related]
2. Dynamic and kinetic effects of chronic citalopram treatment in experimental hepatic encephalopathy.
Apelqvist G; Wikell C; Carlsson B; Hjorth S; Bergqvist PB; Ahlner J; Bengtsson F
Clin Neuropharmacol; 2000; 23(6):304-17. PubMed ID: 11575864
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver.
Rochat B; Kosel M; Boss G; Testa B; Gillet M; Baumann P
Biochem Pharmacol; 1998 Jul; 56(1):15-23. PubMed ID: 9698084
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective single-dose kinetics of citalopram and its metabolites in rats.
Kugelberg FC; Carlsson B; Ahlner J; Bengtsson F
Chirality; 2003 Aug; 15(7):622-9. PubMed ID: 12840828
[TBL] [Abstract][Full Text] [Related]
5. In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats.
Kugelberg FC; Apelqvist G; Carlsson B; Ahlner J; Bengtsson F
Br J Pharmacol; 2001 Apr; 132(8):1683-90. PubMed ID: 11309239
[TBL] [Abstract][Full Text] [Related]
6. Postmortem redistribution of the enantiomers of citalopram and its metabolites: an experimental study in rats.
Kugelberg FC; Druid H; Carlsson B; Ahlner J; Bengtsson F
J Anal Toxicol; 2004; 28(8):631-7. PubMed ID: 15538956
[TBL] [Abstract][Full Text] [Related]
7. Analytical procedures for the determination of the selective serotonin reuptake inhibitor antidepressant citalopram and its metabolites.
Unceta N; Goicolea MA; Barrio RJ
Biomed Chromatogr; 2011 Jan; 25(1-2):238-57. PubMed ID: 21058412
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic consequences of a citalopram treatment discontinuation.
Voirol P; Rubin C; Bryois C; Kosel M; Buclin T; Baumann P
Ther Drug Monit; 1999 Jun; 21(3):263-6. PubMed ID: 10365634
[TBL] [Abstract][Full Text] [Related]
9. Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: implications for thymoleptic drug safety in liver insufficiency.
Bergqvist PB; Wikell C; Hjorth S; Apelqvist G; Bengtsson F
Clin Neuropharmacol; 1997 Dec; 20(6):511-22. PubMed ID: 9403225
[TBL] [Abstract][Full Text] [Related]
10. Early-phase postmortem redistribution of the enantiomers of citalopram and its demethylated metabolites in rats.
Kugelberg FC; Kingbäck M; Carlsson B; Druid H
J Anal Toxicol; 2005; 29(4):223-8. PubMed ID: 15975250
[TBL] [Abstract][Full Text] [Related]
11. Enantiomeric screening of racemic citalopram and metabolites in human urine by entangled polymer solution capillary electrophoresis: an innovatory robustness/ruggedness study.
Berzas-Nevado JJ; Villaseñor-Llerena MJ; Guiberteau-Cabanillas C; Rodríguez-Robledo V
Electrophoresis; 2006 Feb; 27(4):905-17. PubMed ID: 16470634
[TBL] [Abstract][Full Text] [Related]
12. [Mechanisms of action of antidepressants: new data from Escitalopram].
Fabre V; Hamon M
Encephale; 2003; 29(3 Pt 1):259-65. PubMed ID: 12876551
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997.
Reis M; Lundmark J; Bengtsson F
Ther Drug Monit; 2003 Apr; 25(2):183-91. PubMed ID: 12657912
[TBL] [Abstract][Full Text] [Related]
14. [Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].
Mnie-Filali O; El Mansari M; Scarna H; Zimmer L; Sánchez C; Haddjeri N
Encephale; 2007 Dec; 33(6):965-72. PubMed ID: 18789789
[TBL] [Abstract][Full Text] [Related]
15. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
Mansari ME; Wiborg O; Mnie-Filali O; Benturquia N; Sánchez C; Haddjeri N
Int J Neuropsychopharmacol; 2007 Feb; 10(1):31-40. PubMed ID: 16448580
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.
Sánchez C; Bergqvist PB; Brennum LT; Gupta S; Hogg S; Larsen A; Wiborg O
Psychopharmacology (Berl); 2003 Jun; 167(4):353-62. PubMed ID: 12719960
[TBL] [Abstract][Full Text] [Related]
17. The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram.
Arborelius L; Nomikos GG; Hertel P; Salmi P; Grillner P; Höök BB; Hacksell U; Svensson TH
Naunyn Schmiedebergs Arch Pharmacol; 1996 May; 353(6):630-40. PubMed ID: 8738296
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography.
Kosel M; Eap CB; Amey M; Baumann P
J Chromatogr B Biomed Sci Appl; 1998 Nov; 719(1-2):234-8. PubMed ID: 9869386
[TBL] [Abstract][Full Text] [Related]
19. Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium.
Rochat B; Baumann P; Audus KL
Brain Res; 1999 Jun; 831(1-2):229-36. PubMed ID: 10412001
[TBL] [Abstract][Full Text] [Related]
20. [Behavioral and neurochemical study on the mechanism of the anxiolytic effect of a selective serotonin reuptake inhibitor, a selective serotonin1A agonist and lithium carbonate].
Muraki I
Hokkaido Igaku Zasshi; 2001 Mar; 76(2):57-70. PubMed ID: 11344903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
